Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Research Letters
Open Access

Prolonged SARS-CoV-2 Viral RNA Shedding and IgG Antibody Response to SARS-CoV-2 in Patients on Hemodialysis

Aisha Shaikh, Etti Zeldis, Kirk N. Campbell and Lili Chan
CJASN February 2021, 16 (2) 290-292; DOI: https://doi.org/10.2215/CJN.11120720
Aisha Shaikh
1Division of Nephrology, James J. Peters Veterans Affairs Medical Center, Bronx, New York
2Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Etti Zeldis
1Division of Nephrology, James J. Peters Veterans Affairs Medical Center, Bronx, New York
2Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirk N. Campbell
2Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lili Chan
2Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • COVID-19
  • hemodialysis
  • RNA
  • viral
  • immunoglobulin G

Patients with kidney failure are susceptible to coronavirus disease 2019 (COVID-19) and have a suboptimal seroconversion response to common vaccines (1). Whether patients on maintenance hemodialysis (HD) develop antibodies in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is not well documented. Additionally, the duration of SARS-CoV-2 viral RNA shedding among patients on maintenance HD with COVID-19 has not been extensively studied. We describe a case series of patients on maintenance HD at a single dialysis center in New York, in whom serial SARS-CoV-2 RNA and IgG antibody testing was performed.

COVID-19 was diagnosed in accordance with the Centers for Disease Control and Prevention guidelines (2). Surveillance swabs were performed once on all asymptomatic patients on HD. Patients with a positive SARS-CoV-2 RNA on nasal or nasopharyngeal specimen were considered to have confirmed COVID-19. We could not distinguish the location of the specimen sampling as this information was not included in the collection labels. Patients who presented to the HD center with signs or symptoms suggestive of COVID-19 were tested for SARS-CoV-2 RNA (Cepheid or Abbot SARS-CoV-2 RNA assay). Those with confirmed COVID-19 were subsequently retested longitudinally for SARS-CoV-2 RNA to document clearance of the virus. SARS-CoV-2 IgG antibody testing was performed on patients on HD with confirmed COVID-19 (Abbot IgG nucleocapsid antibody test, reference range for antibody positivity is >1.39). Serial SARS-CoV-2 IgG antibody tests were performed at 2-week intervals for a total of 4 weeks following the initial antibody test. The study was granted an exemption by the Institutional Review Board committee at the James J. Peters Veterans Affairs Medical Center.

Of the 85 patients on maintenance HD at this center, 26% (22 of 85) were diagnosed with COVID-19. All patients, except one, presented to the HD center with signs or symptoms of COVID-19. One patient was asymptomatic and diagnosed with COVID-19 on surveillance SARS-CoV-2 RNA swab. Patient characteristics are presented in Figure 1A. Of the 22 patients diagnosed with COVID-19, 64% (14 of 22) required hospitalization, and five patients required admission to the intensive care unit; 27% (six of 22) of patients died, five deaths occurred during hospitalization, and one patient died following hospital discharge. Death occurred after a median of 31.5 days (range, 6–80) following the diagnosis of COVID-19. Three of the patients who were COVID-19 positive died before repeat PCR or initial antibody testing could be performed.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Hemodialysis patients with coronavirus disease 2019 (COVID-19) have prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA shedding and mount an IgG antibody response. (A) Butterfly plot of patient characteristics in patients on hemodialysis who tested positive and tested negative for COVID-19. *Statistical significance with P=0.05. (B) Results of serial SARS-CoV-2 RNA testing. Vertical lines within the bars indicate when each test was performed. Blue bars indicate the test was positive, whereas gray bars indicate the test was negative. *Patients who tested positive again following two consecutive negative swabs. (C) Serial antibody titer data by patient.

Additionally, 86% (19 of 22) had repeat SARS-CoV-2 RNA testing after a median of 14 days (range, 9–39) following the initial positive PCR test (Figure 1B); 68% (13 of 19) of patients continued to test positive for SARS-CoV-2 RNA on repeat testing after 20 days, and 32% (six of 19) of patients continued to test positive 40 days after the first SARS-CoV-2–positive test. Two patients died with positive SARS-CoV-2 RNA tests, and the remaining 17 patients had two consecutive negative swabs at a median of 30 days (range, 12–56). Five patients tested positive for SARS-CoV-2 RNA on repeat testing despite being negative on two prior consecutive nasal or nasopharyngeal specimens after a median of 52 days (range, 38–74) following the COVID-19 diagnosis. Four of five of these patients were asymptomatic at the time of the repeat positive test, and one patient was hospitalized and ventilator dependent.

IgG antibody test was performed on 86% (19 of 22) of patients after a median of 35 days (range, 17–48) following the diagnosis of COVID-19. All 19 patients tested positive for IgG antibody on the initial test, with a median antibody titer of 7.2 (interquartile range [IQR], 6.6–7.8). Serial IgG antibody testing was performed at 2- and 4-week intervals following the initial antibody test in 18 of 19 surviving patients, and the median antibody titers were 7.6 (IQR, 7.15–7.92) and 8.95 (IQR, 8.22–9.93), respectively (Figure 1C). One patient died before serial antibody testing could be performed. Antibodies were positive after a median of 63 days (range, 46–81) following COVID-19 diagnosis in all patients. There was no significant difference between median antibody titers of patients who required hospitalization and those who did not: 7.4 (IQR, 6.41–7.95) versus 7.86 (IQR, 7.59–8.15; P=0.18). In 37% (seven of 19) of patients, the SARS-CoV-2 RNA was detectable despite the presence of IgG antibody.

The significance of prolonged viral RNA shedding among patients on HD with COVID-19 who have symptomatically recovered and have developed SARS-CoV-2 IgG antibody remains unknown (3) (van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, van den Akker JPC, Endeman H, Gommers DAMPJ, Cornelissen JJ, Hoek RAS, van der Eerden MM, Hesselink DA, Metselaar HJ, Verbon A, de Steenwinkel JEM, Aron GI, van Gorp ECM, van Boheemen S, Voermans JC, Boucher CAB, Molenkamp R, Koopmans MPG, Geurtsvankessel C, van der Eijk AA: Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): Duration and key determinants. medRxiv, 2020 10.1101/2020.06.08.20125310). Prolonged viral RNA shedding could have a substantial effect on the workflow of the HD center. Defining when the shed viral particles are no longer infectious is, therefore, a crucial unmet need. A recent study reported IgG antibody seroconversion in 100% (six of six) patients on HD with COVID-19 (4). This is consistent with our findings where all patients on maintenance HD with COVID-19 developed SARS-CoV-2 IgG antibody. The development of IgG antibody by all of the patients on HD in response to COVID-19 is encouraging, but whether the IgG antibodies persist or if they confer immunity, protecting patients against future SARS-CoV-2 infection, remains to be seen.

Disclosures

All authors have nothing to disclose.

Funding

None.

Acknowledgments

We acknowledge the hemodialysis staff at the James J. Peters Veterans Affairs Medical Center who were involved in the care of patients during the COVID-19 pandemic.

K. Campbell, L. Chan, A. Shaikh, and E. Zeldis designed the study, analyzed the data, and drafted the manuscript.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2021 by the American Society of Nephrology

References

  1. ↵
    1. Soni R,
    2. Horowitz B,
    3. Unruh M
    : Immunization in end-stage renal disease: Opportunity to improve outcomes. Semin Dial 26: 416–426, 2013 pmid:23751048
    OpenUrlCrossRefPubMed
  2. ↵
    1. Centers for Disease Control and Prevention
    : Coronavirus Disease 2019 (COVID-19), 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed August 1, 2020
  3. ↵
    1. Wölfel R,
    2. Corman VM,
    3. Guggemos W,
    4. Seilmaier M,
    5. Zange S,
    6. Müller MA,
    7. Niemeyer D,
    8. Jones TC,
    9. Vollmar P,
    10. Rothe C,
    11. Hoelscher M,
    12. Bleicker T,
    13. Brünink S,
    14. Schneider J,
    15. Ehmann R,
    16. Zwirglmaier K,
    17. Drosten C,
    18. Wendtner C
    : Virological assessment of hospitalized patients with COVID-2019. Nature 581: 465–469, 2020 pmid:32235945
    OpenUrlCrossRefPubMed
  4. ↵
    1. De Vriese AS,
    2. Reynders M
    : IgG antibody response to SARS-CoV-2 infection and viral RNA persistence in patients on maintenance hemodialysis. Am J Kidney Dis 76: 440–441, 2020 pmid:32512038
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 16 (2)
Clinical Journal of the American Society of Nephrology
Vol. 16, Issue 2
February 08, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Prolonged SARS-CoV-2 Viral RNA Shedding and IgG Antibody Response to SARS-CoV-2 in Patients on Hemodialysis
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prolonged SARS-CoV-2 Viral RNA Shedding and IgG Antibody Response to SARS-CoV-2 in Patients on Hemodialysis
Aisha Shaikh, Etti Zeldis, Kirk N. Campbell, Lili Chan
CJASN Feb 2021, 16 (2) 290-292; DOI: 10.2215/CJN.11120720

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Prolonged SARS-CoV-2 Viral RNA Shedding and IgG Antibody Response to SARS-CoV-2 in Patients on Hemodialysis
Aisha Shaikh, Etti Zeldis, Kirk N. Campbell, Lili Chan
CJASN Feb 2021, 16 (2) 290-292; DOI: 10.2215/CJN.11120720
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Effect of Sickle Cell Trait and APOL1 Genotype on the Association of Soluble uPAR with Kidney Function Measures in Black Americans
  • Characteristics of Acute Kidney Injury in Hospitalized COVID-19 Patients in an Urban Academic Medical Center
Show more Research Letters

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • COVID-19
  • hemodialysis
  • RNA
  • viral
  • immunoglobulin G

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire